CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...
Phase 3
Sandy Springs, Georgia, United States and 36 other locations
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...
Phase 3
Sandy Springs, Georgia, United States and 41 other locations
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...
Phase 2
Sandy Springs, Georgia, United States and 26 other locations
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Phase 2
Atlanta, Georgia, United States and 79 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Sandy Springs, Georgia, United States and 83 other locations
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...
Phase 3
Marietta, Georgia, United States and 100 other locations
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have...
Phase 2
Fayetteville, Georgia, United States and 89 other locations
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...
Phase 2
Fayetteville, Georgia, United States and 95 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Norcross, Georgia, United States and 561 other locations
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Phase 3
Sandy Springs, Georgia, United States and 320 other locations
Clinical trials
Research sites
Resources
Legal